MY-5445
CAS No. 78351-75-4
MY-5445 ( N-(3-chlorophenyl)-4-phenylphthalazin-1-amine )
产品货号. M26765 CAS No. 78351-75-4
MY-5445 是 5 型磷酸二酯酶 (PDE5) 的特异性抑制剂。 MY-5445 选择性抑制 cGMP PDE (Ki:1.3 μM)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥367 | 有现货 |
|
| 10MG | ¥568 | 有现货 |
|
| 25MG | ¥1088 | 有现货 |
|
| 50MG | ¥1646 | 有现货 |
|
| 100MG | ¥2349 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥406 | 有现货 |
|
生物学信息
-
产品名称MY-5445
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述MY-5445 是 5 型磷酸二酯酶 (PDE5) 的特异性抑制剂。 MY-5445 选择性抑制 cGMP PDE (Ki:1.3 μM)。
-
产品描述MY-5445 is a specific inhibitor of phosphodiesterase type 5 (PDE5). MY-5445 selectively inhibits cGMP PDE (Ki:1.3 μM).(In Vitro): in ABCG2-overexpressing cells, MY-5445 selectively reverses ABCG2-mediated multidrug resistance. MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2. In the S1-M1-80 cell, MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis.(In Vivo):I.p administration of 0.5-3 mg/kg twice a day for 15 days) produces significant relief of mechanical hypersensitivity.
-
体外实验MY-5445 inhibits human platelet aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclic GMP in platelet aggregation .MY-5445 selectively reverses ABCG2-mediated multidrug resistance in ABCG2-overexpressing cells.MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2.MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis in S1-M1-80 cell. Apoptosis Analysis Cell Line:Human S1 colon cancer cells, S1-M1-80 cancer cells Concentration:3 μM Incubation Time:48 hours Result:Enhanced drug-induced apoptosis in ABCG2-overexpressing cancer cells.
-
体内实验MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity. Animal Model:C57BL/6J male mice Dosage:0.5 mg/kg, 3 mg/kg Administration:Intraperitoneal injection, twice a day, for 15 daysResult:Alleviated the cuff-induced allodynia.
-
同义词N-(3-chlorophenyl)-4-phenylphthalazin-1-amine
-
通路Angiogenesis
-
靶点PDE
-
受体DHFR
-
研究领域——
-
适应症——
化学信息
-
CAS Number78351-75-4
-
分子量331.8
-
分子式C20H14ClN3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 50 mg/mL (150.69 mM)
-
SMILESClc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019;62(3):1562-1576.
产品手册
关联产品
-
UK-369003
UK-369003(苯磺酸吉沙地那非)是一种新型、有效、选择性、口服生物可利用的 PDE5 抑制剂,IC50 为 1.23 nM。
-
Vardenafil
伐地那非(艾力达)是一种治疗勃起功能障碍的口服疗法。
-
Mirodenafil
Mirodenafil (SK3530) 是一种口服有效、可逆的、选择性的磷酸二酯酶 5 (PDE5) 的抑制剂。Mirodenafil 是一种糖皮质激素受体 (GR) 的调节剂。Mirodenafil 通过下调 Dkk1 的表达,激活 Wnt/β-catenin 信号通路。Mirodenafil 可用于研究勃起功能障碍 (ED)、阿尔茨海默病 (AD) 和系统性硬化症 (SSc)。
021-51111890
购物车()
sales@molnova.cn

